These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 26147692)

  • 1. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
    Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
    FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
    Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
    Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
    Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
    Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.
    Kimura A; Hata S; Suzuki T
    J Biol Chem; 2016 Nov; 291(46):24041-24053. PubMed ID: 27687728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
    Stockley JH; O'Neill C
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
    Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
    Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells.
    Cao G; Su P; Zhang S; Guo L; Zhang H; Liang Y; Qin C; Zhang W
    Eur J Pharmacol; 2016 Dec; 793():101-108. PubMed ID: 27840193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cells.
    Chen LM; Lin ZY; Zhu YG; Lin N; Zhang J; Pan XD; Chen XC
    Eur J Pharmacol; 2012 Jan; 675(1-3):15-21. PubMed ID: 22166376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.
    Devi L; Ohno M
    Neuroscience; 2015 Oct; 307():128-37. PubMed ID: 26314636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing.
    Rabe S; Reichwald J; Ammaturo D; de Strooper B; Saftig P; Neumann U; Staufenbiel M
    J Neurochem; 2011 Oct; 119(1):231-9. PubMed ID: 21812781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42.
    Buggia-Prevot V; Sevalle J; Rossner S; Checler F
    J Biol Chem; 2008 Apr; 283(15):10037-47. PubMed ID: 18263584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.
    Nishitomi K; Sakaguchi G; Horikoshi Y; Gray AJ; Maeda M; Hirata-Fukae C; Becker AG; Hosono M; Sakaguchi I; Minami SS; Nakajima Y; Li HF; Takeyama C; Kihara T; Ota A; Wong PC; Aisen PS; Kato A; Kinoshita N; Matsuoka Y
    J Neurochem; 2006 Dec; 99(6):1555-63. PubMed ID: 17083447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.
    Arbel-Ornath M; Becker M; Rabinovich-Toidman P; Gartner M; Solomon B
    J Alzheimers Dis; 2010; 22(2):469-82. PubMed ID: 20847413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.